← Human Trials & Peer-Reviewed Studies
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial
Plain-language guide to PMID 39546502 (2024): randomized controlled trial study of Insulin Glargine and Liraglutide in 5,047 participants.
Key Facts
- PMID
- 39546502
- Journal
- PloS one
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Seaquist ER et al. (16 authors)
- DOI
- 10.1371/journal.pone.0309907
- Registered trial
- NCT01794143
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Glargine and Liraglutide in this randomized controlled trial publication.
Hypoglycemia is a major concern in type 2 diabetes (T2DM), but little is known about its likelihood compared across common therapies.
Who Took Part
According to the abstract, 5,047 participants were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized.
The participants were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.
Randomization to addition of glargine U100, glimepiride, liraglutide, or sitagliptin over 5.0 ± 1.3 (mean ± SD) years.
The researchers assessed severe hypoglycemia events reported throughout the entire study.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin Glargine and Liraglutide.
What This Means in Plain Language
The paper is a randomized study of Insulin Glargine and Liraglutide in 5,047 participants.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (PloS one), a journal based in United States.
More context: the Insulin Glargine compound page and the Liraglutide compound page, all human trials.
Our Notes on the Compounds
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.